Grifols Strengthens Evidence For AMBAR In Alzheimer's With RWE Data

By Reuters News

- Grifols, S.A. GRLS.MC:

  • STRENGTHENS EVIDENCE FOR AMBAR PROGRAM WITH NEW RWE DATA

  • AMBAR STUDY HAS SHOWN 61% REDUCTION IN DISEASE PROGRESSION IN PATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE COMPARED WITH UNTREATED PATIENTS

  • AMBAR PROTOCOL BEGINS IMPLEMENTATION AT HOSPITALS IN SPAIN

  • COMPANY IALSO IN DISCUSSIONS WITH OTHER HOSPITALS ACROSS SPAIN TO EXPLORE PROGRESSIVE ADOPTION OF PROTOCOL AT ADDITIONAL CENTERS

  • FINDINGS EXPAND EVIDENCE RE APPLICABILITY OF THERAPEUTIC PLASMA EXCHANGE WITH ALBUMIN REPLACEMENT UNDER ROUTINE CLINICAL PRACTICE CONDITIONS

Source text: [ID:]

Further company coverage: GRLS.MC

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk